Envista (NVST) 2026 Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
2026 Global Healthcare Conference summary
15 Sep, 2026Market and business performance
Dental market rebounded post-COVID, with growth returning to pre-pandemic trends in most categories.
Consumables outperformed due to higher dental inflation and insulation from consumer sentiment, especially in the U.S.
Equipment and diagnostics saw a post-pandemic surge, with diagnostics now the fastest-growing category due to innovation and easy comps.
North America remains the largest and fastest-growing market for core businesses, with efforts to expand internationally.
Developing markets (excluding China) and Europe are experiencing the fastest growth, while China lags due to VBP policy.
Pricing, inflation, and financial strategy
Dental market price inflation typically runs at or above CPI, with current company pricing at about 1.8%.
Recent price increases were supported by external factors like tariffs and raw material costs, but long-term price growth is expected to be 1–1.5%.
Financial performance has improved across the P&L, with gains in market share and balance sheet strength.
Dental implants and specialty segments
Global dental implant market grows mid-single digits, with premium segment slower and challenger segment faster.
Company over-indexes in premium implants (85% of mix), aiming to grow challenger share organically and through M&A.
Recent acquisitions focused on implants, with preference for deals that are accretive on growth, margin, and valuation.
Workflow and digital solutions drive growth in premium implants, while regenerative products and diagnostics outperform the core implant product.
Latest events from Envista
- Strong Q2 growth, margin expansion, and raised 2026 guidance amid resilient markets.NVST
Q2 2026 - All proposals passed, directors elected, and no stockholder questions were raised.NVST
AGM 2026 - Q1 2026 saw strong sales, margin expansion, and a $300M buyback with guidance reaffirmed.NVST
Q1 2026 - Key votes include director elections, auditor ratification, and executive pay approval.NVST
Proxy filing - Annual meeting to vote on directors, auditor, executive pay, and ESG priorities.NVST
Proxy filing - Double-digit core sales, EBITDA, and EPS growth in 2025, with strong 2026 outlook.NVST
Q4 2025 - Q3 2025 delivered 9.4% core growth, 14.5% EBITDA margin, and raised full-year guidance.NVST
Q3 2025 - Q2 loss of $1.15B on impairments; sales and margins fell, but cash flow improved and Q4 growth is expected.NVST
Q2 2024 - Q4 core sales rose 2% with strong cash flow and a $250M share repurchase plan.NVST
Q4 2024